After dealing with a deployment issue with glucose monitors earlier this year, interim CEO Jake Leach said improving customer ...

Q3 2025 Earnings Call Transcript October 30, 2025 DexCom, Inc. beats earnings expectations. Reported EPS is $0.61, ...

Medical device company DexCom (NASDAQ:DXCM) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales ...

DexCom, Inc. DXCM reported third-quarter 2025 adjusted earnings per share (EPS) of 61 cents, which beat the Zacks Consensus ...

DexCom Inc (DXCM) reports a robust 22% increase in worldwide revenue, driven by expanded CGM access and strategic market ...

Get key insights from DexCom’s Q3 2025 earnings: robust revenue growth, new product launches, updated guidance, and future opportunities.

Thank you, operator, and welcome to DexCom's Third Quarter 2025 Earnings Call. Our agenda begins with Jake Leach, DexCom's President and Interim CEO, who will summarize our recent highlights and ...

DexCom posts Q3 revenue of $1.21 billion, beating estimates and raising 2025 guidance as analysts expect strong sales and margin improvement ahead.

Dexcom (($DXCM)) has held its Q3 earnings call. Read on for the main highlights of the call. DexCom’s recent earnings call conveyed a generally ...

Dexcom Inc. executives may have thought a $30 million beat ... following issues with its G7 sensor, which management said have been largely resolved.

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM) securities during ...

Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...